TTNP Stock Overview
A pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Titan Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.34 |
| 52 Week High | US$14.80 |
| 52 Week Low | US$3.03 |
| Beta | 1.11 |
| 1 Month Change | -3.75% |
| 3 Month Change | -32.93% |
| 1 Year Change | -47.98% |
| 3 Year Change | -83.47% |
| 5 Year Change | -98.33% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?
Jul 10
Titan Pharma regains Nasdaq listing compliance
Dec 16Titan Pharmaceuticals announces 1-for-30 reverse stock split
Nov 30Titan Pharmaceuticals EPS misses by $0.01, beats on revenue
Nov 16Titan Pharma closes debt settlement and JT-09 acquisition
Nov 02Titan Pharma to raise $8M in stock offering
Oct 28Shareholder Returns
| TTNP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.4% | 0.4% | -2.1% |
| 1Y | -48.0% | 2.2% | 21.3% |
Return vs Industry: TTNP underperformed the US Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: TTNP underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| TTNP volatility | |
|---|---|
| TTNP Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TTNP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TTNP's weekly volatility has decreased from 19% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 4 | Weei Chay | www.titanpharm.com |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Titan Pharmaceuticals, Inc. Fundamentals Summary
| TTNP fundamental statistics | |
|---|---|
| Market cap | US$3.09m |
| Earnings (TTM) | -US$5.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs TTNP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TTNP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$487.00k |
| Gross Profit | -US$487.00k |
| Other Expenses | US$5.40m |
| Earnings | -US$5.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TTNP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 04:58 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Titan Pharmaceuticals, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| Michael Higgins | Brinson Patrick Securities Corporation |
| Jason McCarthy | Maxim Group |